NO327009B1 - Nye forbindelser, fremgangsmate for fremstilling derav, anvendelse av forbindelsen samt farmasoytisk preparat omfattende denne - Google Patents
Nye forbindelser, fremgangsmate for fremstilling derav, anvendelse av forbindelsen samt farmasoytisk preparat omfattende denne Download PDFInfo
- Publication number
- NO327009B1 NO327009B1 NO20041003A NO20041003A NO327009B1 NO 327009 B1 NO327009 B1 NO 327009B1 NO 20041003 A NO20041003 A NO 20041003A NO 20041003 A NO20041003 A NO 20041003A NO 327009 B1 NO327009 B1 NO 327009B1
- Authority
- NO
- Norway
- Prior art keywords
- pain
- pharmaceutically acceptable
- solvate
- compound
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 56
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000012453 solvate Substances 0.000 claims description 22
- 208000002193 Pain Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 13
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- GOOVAYJIVMBWPP-UHFFFAOYSA-N 1-bromo-2-isocyanatobenzene Chemical compound BrC1=CC=CC=C1N=C=O GOOVAYJIVMBWPP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- YSMPURKYECKBKX-MRVPVSSYSA-N (3r)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-amine Chemical compound C1[C@H](N)CCN1C1=CC=C(C(F)(F)F)C=N1 YSMPURKYECKBKX-MRVPVSSYSA-N 0.000 claims description 2
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010054949 Metaplasia Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 206010030216 Oesophagitis Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010038419 Renal colic Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims description 2
- 230000002917 arthritic effect Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000007885 bronchoconstriction Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000015689 metaplastic ossification Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000003349 osteoarthritic effect Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 102000011040 TRPV Cation Channels Human genes 0.000 description 7
- 108010062740 TRPV Cation Channels Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000017663 capsaicin Nutrition 0.000 description 4
- 229960002504 capsaicin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JYILLRHXRVTRSH-GFCCVEGCSA-N 1-(2-bromophenyl)-3-[(3r)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]urea Chemical compound N1=CC(C(F)(F)F)=CC=C1N1C[C@H](NC(=O)NC=2C(=CC=CC=2)Br)CC1 JYILLRHXRVTRSH-GFCCVEGCSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GJKCYSMZYSMYRW-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-(1-phenylpyrrolidin-3-yl)urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1CN(C=2C=CC=CC=2)CC1 GJKCYSMZYSMYRW-UHFFFAOYSA-N 0.000 description 1
- DWYHJOLGUSRZSO-UHFFFAOYSA-N 1-phenyl-3-(1-phenylpyrrolidin-3-yl)urea Chemical compound C=1C=CC=CC=1NC(=O)NC(C1)CCN1C1=CC=CC=C1 DWYHJOLGUSRZSO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JFZJMSDDOOAOIV-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)N=C1 JFZJMSDDOOAOIV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- -1 4-hydroxy-3-methoxybenzyl) group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- DRCMAZOSEIMCHM-UHFFFAOYSA-N capsazepine Chemical compound C1C=2C=C(O)C(O)=CC=2CCCN1C(=S)NCCC1=CC=C(Cl)C=C1 DRCMAZOSEIMCHM-UHFFFAOYSA-N 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 description 1
- 229950010717 olvanil Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- XGBULVIMVCHZSV-UHFFFAOYSA-N pyrrolidin-3-ylurea Chemical class NC(=O)NC1CCNC1 XGBULVIMVCHZSV-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0122156A GB0122156D0 (en) | 2001-09-13 | 2001-09-13 | Novel compounds |
| GB0130503A GB0130503D0 (en) | 2001-12-20 | 2001-12-20 | Novel compounds |
| GB0130505A GB0130505D0 (en) | 2001-12-20 | 2001-12-20 | Novel compounds |
| GB0130547A GB0130547D0 (en) | 2001-12-20 | 2001-12-20 | Novel compounds |
| PCT/GB2002/004206 WO2003022809A2 (fr) | 2001-09-13 | 2002-09-13 | Nouveaux composes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20041003L NO20041003L (no) | 2004-06-04 |
| NO327009B1 true NO327009B1 (no) | 2009-04-06 |
Family
ID=27447989
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20041003A NO327009B1 (no) | 2001-09-13 | 2004-03-10 | Nye forbindelser, fremgangsmate for fremstilling derav, anvendelse av forbindelsen samt farmasoytisk preparat omfattende denne |
| NO20085077A NO20085077L (no) | 2001-09-13 | 2008-12-04 | Nye forbindelser |
| NO20085078A NO20085078L (no) | 2001-09-13 | 2008-12-04 | Nye forbindelser |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20085077A NO20085077L (no) | 2001-09-13 | 2008-12-04 | Nye forbindelser |
| NO20085078A NO20085078L (no) | 2001-09-13 | 2008-12-04 | Nye forbindelser |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8063078B2 (fr) |
| EP (3) | EP2036902A3 (fr) |
| JP (2) | JP4463552B2 (fr) |
| KR (3) | KR100955967B1 (fr) |
| CN (1) | CN1247568C (fr) |
| AP (1) | AP1818A (fr) |
| AR (1) | AR038786A1 (fr) |
| AT (1) | ATE420083T1 (fr) |
| AU (1) | AU2002329397B2 (fr) |
| BR (1) | BR0212468A (fr) |
| CA (1) | CA2458632C (fr) |
| CY (1) | CY1109449T1 (fr) |
| DE (1) | DE60230773D1 (fr) |
| DK (1) | DK1425277T3 (fr) |
| EA (1) | EA007731B1 (fr) |
| ES (1) | ES2316607T3 (fr) |
| HK (1) | HK1066534A1 (fr) |
| HU (1) | HUP0401923A3 (fr) |
| IL (2) | IL160755A0 (fr) |
| MA (1) | MA26216A1 (fr) |
| MX (1) | MXPA04002379A (fr) |
| MY (1) | MY138086A (fr) |
| NO (3) | NO327009B1 (fr) |
| NZ (1) | NZ531137A (fr) |
| OA (1) | OA12659A (fr) |
| PE (1) | PE20030417A1 (fr) |
| PL (1) | PL213639B1 (fr) |
| PT (1) | PT1425277E (fr) |
| SI (1) | SI1425277T1 (fr) |
| TW (1) | TWI283665B (fr) |
| UY (1) | UY27446A1 (fr) |
| WO (1) | WO2003022809A2 (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI283665B (en) | 2001-09-13 | 2007-07-11 | Smithkline Beecham Plc | Novel urea compound, pharmaceutical composition containing the same and its use |
| PT1472225E (pt) | 2002-02-01 | 2010-07-30 | Euro Celtique Sa | 2-piperazina-piridinas uteis para tratar a dor |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| CA2476936A1 (fr) * | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Composes azabicycliques fusionnes qui inhibent le recepteur (vr1) sous-type 1 du recepteur vanilloide |
| US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| WO2004002983A2 (fr) | 2002-06-28 | 2004-01-08 | Euro-Celtique, S.A. | Agents therapeutiques utiles pour le traitement de la douleur |
| US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| GB0221157D0 (en) * | 2002-09-12 | 2002-10-23 | Glaxo Group Ltd | Novel treatment |
| WO2004024710A1 (fr) * | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7381840B2 (en) | 2002-12-06 | 2008-06-03 | Xention Limited | Tetrahydro-naphthalene derivatives |
| GB0229808D0 (en) * | 2002-12-20 | 2003-01-29 | Glaxo Group Ltd | Novel compositions |
| US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| JP2006519826A (ja) | 2003-03-06 | 2006-08-31 | グラクソ グループ リミテッド | 疼痛治療のための複素環式尿素誘導体 |
| EP1601665A2 (fr) * | 2003-03-07 | 2005-12-07 | Glaxo Group Limited | Derives d'uree |
| GB0305426D0 (en) * | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| WO2004103954A1 (fr) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | Derive d'amide |
| EP1493438A1 (fr) * | 2003-07-03 | 2005-01-05 | Bayer HealthCare AG | Inhibiteurs du recepteur vanilloide (VR1) dans le traitement de la douleur associée au VIH |
| GB0319150D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| GB0319151D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| DE602004019294D1 (de) * | 2003-10-01 | 2009-03-19 | Xention Ltd | Tetrahydronaphthalin- und harnstoffderivate |
| WO2005035471A1 (fr) | 2003-10-14 | 2005-04-21 | Ajinomoto Co., Inc. | Derive ethere |
| CA2542494A1 (fr) * | 2003-10-15 | 2005-05-06 | Bayer Healthcare Ag | Derives de tetrahydro-naphthalene et d'uree |
| US7683076B2 (en) | 2003-11-08 | 2010-03-23 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydro-quinolinylurea derivatives |
| EP1736465A4 (fr) * | 2004-03-31 | 2009-06-17 | Ajinomoto Kk | Dérivés d'aniline |
| WO2006002361A2 (fr) | 2004-06-24 | 2006-01-05 | Incyte Corporation | 2-methylpropanamides et leur utilisation comme produits pharmaceutiques |
| US7879866B2 (en) | 2004-07-19 | 2011-02-01 | Dorte Xenia Gram | Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders |
| KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| WO2006098554A1 (fr) * | 2005-03-16 | 2006-09-21 | Amorepacific Corporation | Nouveaux composes, isomere de ceux-ci ou sels pharmaceutiquement acceptables de ceux-ci en tant qu’antagonistes du recepteur vanilloide ; et composition pharmaceutique contenant ceux-ci |
| WO2007046867A2 (fr) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Derives de piperidine et leurs utilisations comme agents therapeutiques |
| UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| EP1889830A1 (fr) * | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | Amides biarylcarboxyaryles en tant que modulateurs du recepteur vanilloid-1. |
| EP2054411B1 (fr) * | 2006-07-27 | 2014-08-20 | Amorepacific Corporation | Nouveaux composés, isomères de ceux-ci, ou sels acceptables sur le plan pharmaceutique de ceux-ci utilisés en tant qu'antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant |
| EP1882687A1 (fr) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Composés hétérocycliques, leur utilisation comme antagonistes du récepteur vanilloide et les compositions pharmaceutiques qui les contiennent |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| EP2054390B1 (fr) | 2006-08-25 | 2012-04-11 | Abbott Laboratories | Dérivés d'indazole inhibant trpv1, et leur utilisation |
| JP2010513557A (ja) | 2006-12-20 | 2010-04-30 | アボット・ラボラトリーズ | 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物 |
| EP2489660A1 (fr) | 2008-03-20 | 2012-08-22 | Abbott Laboratories | Procédés de fabrication d'agents de système nerveux central qui sont des antagonistes TRPV1 |
| EP2264031B1 (fr) | 2008-04-18 | 2015-04-15 | Daewoong Pharmaceutical Co., Ltd. | Nouveau dérivé de benzoxazine benzimidazole, composition pharmaceutique le comprenant et application s'y rapportant |
| JP4746713B2 (ja) * | 2008-05-07 | 2011-08-10 | 大日本住友製薬株式会社 | 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
| WO2010026128A1 (fr) * | 2008-09-02 | 2010-03-11 | Glaxo Group Limited | N-(3-méthyl-5-isoquinolinyl)-n'-((3r)-l-[5-(trifluorométhyl)-2-pyridinyl]-3-pyrrolidinyl) urée pour le traitement de la rhinite |
| JP2012501315A (ja) * | 2008-09-02 | 2012-01-19 | グラクソ グループ リミテッド | 鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８ |
| JP2013028536A (ja) * | 2009-11-11 | 2013-02-07 | Dainippon Sumitomo Pharma Co Ltd | 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物 |
| WO2012045729A1 (fr) | 2010-10-05 | 2012-04-12 | Glaxo Group Limited | Dérivés d'imidazo[1,2-a]pyridine et de pyrazolo[1,5-a]pyridine en tant qu'antagonistes du trpv1 |
| KR101293384B1 (ko) | 2010-10-13 | 2013-08-05 | 주식회사 대웅제약 | 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도 |
| WO2012072512A1 (fr) | 2010-11-29 | 2012-06-07 | Glaxo Group Limited | Carboxamides de n-cyclo-butylimidazopyridine ou de n-cyclo-pyrazolopyridine comme antagonistes de trpv1 |
| GB201101517D0 (en) * | 2011-01-28 | 2011-03-16 | Proximagen Ltd | Receptor antagonists |
| EP2697221A1 (fr) | 2011-04-11 | 2014-02-19 | Glaxo Group Limited | N-cyclobutyl-imidazopyridine-méthylamine à titre d'antagoniste des trpv1 |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3424761A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| US3424760A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
| GB1460389A (en) * | 1974-07-25 | 1977-01-06 | Pfizer Ltd | 4-substituted quinazoline cardiac stimulants |
| DE68918991T2 (de) | 1988-06-17 | 1995-04-27 | Procter & Gamble | Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion. |
| HU206082B (en) | 1988-12-23 | 1992-08-28 | Sandoz Ag | Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds |
| CA2017383A1 (fr) | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Utilisation de vanilloides pour le traitement des affections ou des troubles respiratoires |
| WO1992009285A1 (fr) | 1990-11-27 | 1992-06-11 | The Procter & Gamble Company | Combinaisons de composes vanilloides et de composes phosphonates antiviraux pour le traitement d'infections par herpes |
| US5149704A (en) | 1991-05-03 | 1992-09-22 | Abbott Laboratories | Platelet activating antagonists |
| CA2197364A1 (fr) * | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Compose phenolique et methode de preparation |
| AU8270298A (en) * | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
| CA2294042A1 (fr) * | 1997-06-26 | 1999-01-07 | David Kent Herron | Agents antithrombotiques |
| JP2000080085A (ja) | 1997-09-01 | 2000-03-21 | Kyorin Pharmaceut Co Ltd | ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法 |
| CN1210254C (zh) | 1999-02-22 | 2005-07-13 | 株式会社太平洋 | 作为有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物,其组合物以及应用 |
| ATE278674T1 (de) | 1999-03-12 | 2004-10-15 | Boehringer Ingelheim Pharma | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
| EP1220836A2 (fr) * | 1999-10-15 | 2002-07-10 | Bristol-Myers Squibb Pharma Company | Amines benzyle cycloalkyle comme modulateurs de l'activite du recepteur de la chimiokine |
| NZ523526A (en) | 2000-07-20 | 2004-10-29 | Neurogen Corp | Diaryl piperazines as capsaicin receptor ligands |
| EP1311477A4 (fr) | 2000-08-21 | 2005-01-12 | Pacific Corp | Nouveaux derives d'acide thiocarbamique et compositions pharmaceutiques contenant lesdits derives |
| CN100439332C (zh) | 2000-08-21 | 2008-12-03 | 株式会社太平洋 | 硫脲衍生物以及包含该衍生物的药物组合物 |
| ATE328868T1 (de) | 2000-08-21 | 2006-06-15 | Pacific Corp | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten |
| JP2002080073A (ja) | 2000-09-07 | 2002-03-19 | Kyokuto Kobunshi Kk | 電子レンジ用自動開孔袋 |
| JP2002088073A (ja) * | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| GB0110901D0 (en) | 2001-05-02 | 2001-06-27 | Smithkline Beecham Plc | Novel Compounds |
| TWI283665B (en) * | 2001-09-13 | 2007-07-11 | Smithkline Beecham Plc | Novel urea compound, pharmaceutical composition containing the same and its use |
| CN1678586A (zh) * | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
| WO2004024710A1 (fr) * | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Composes a base d'uree, actifs en tant qu'antagonistes du recepteur de la vanilloide et utilises pour traiter les douleurs |
| GB0229808D0 (en) | 2002-12-20 | 2003-01-29 | Glaxo Group Ltd | Novel compositions |
| CA2563494A1 (fr) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Derives d'uree utilises en tant qu'antagonistes du recepteur vanilloide (vr1) |
-
2002
- 2002-09-11 TW TW091120671A patent/TWI283665B/zh not_active IP Right Cessation
- 2002-09-11 PE PE2002000895A patent/PE20030417A1/es not_active Application Discontinuation
- 2002-09-11 MY MYPI20023391A patent/MY138086A/en unknown
- 2002-09-12 UY UY27446A patent/UY27446A1/es not_active Application Discontinuation
- 2002-09-12 AR ARP020103454A patent/AR038786A1/es active IP Right Grant
- 2002-09-13 DK DK02765023T patent/DK1425277T3/da active
- 2002-09-13 BR BR0212468-8A patent/BR0212468A/pt not_active IP Right Cessation
- 2002-09-13 AU AU2002329397A patent/AU2002329397B2/en not_active Ceased
- 2002-09-13 DE DE60230773T patent/DE60230773D1/de not_active Expired - Lifetime
- 2002-09-13 OA OA1200400070A patent/OA12659A/en unknown
- 2002-09-13 EA EA200400432A patent/EA007731B1/ru not_active IP Right Cessation
- 2002-09-13 HU HU0401923A patent/HUP0401923A3/hu unknown
- 2002-09-13 KR KR1020097003812A patent/KR100955967B1/ko not_active IP Right Cessation
- 2002-09-13 KR KR1020047003680A patent/KR101063679B1/ko not_active IP Right Cessation
- 2002-09-13 EP EP08172882A patent/EP2036902A3/fr not_active Withdrawn
- 2002-09-13 CN CNB028177177A patent/CN1247568C/zh not_active Expired - Fee Related
- 2002-09-13 JP JP2003526885A patent/JP4463552B2/ja not_active Expired - Fee Related
- 2002-09-13 KR KR1020107014626A patent/KR20100082390A/ko not_active Application Discontinuation
- 2002-09-13 PT PT02765023T patent/PT1425277E/pt unknown
- 2002-09-13 NZ NZ531137A patent/NZ531137A/en not_active IP Right Cessation
- 2002-09-13 CA CA2458632A patent/CA2458632C/fr not_active Expired - Fee Related
- 2002-09-13 AT AT02765023T patent/ATE420083T1/de active
- 2002-09-13 SI SI200230792T patent/SI1425277T1/sl unknown
- 2002-09-13 WO PCT/GB2002/004206 patent/WO2003022809A2/fr active Application Filing
- 2002-09-13 PL PL369026A patent/PL213639B1/pl not_active IP Right Cessation
- 2002-09-13 EP EP10179466A patent/EP2298757A3/fr not_active Withdrawn
- 2002-09-13 EP EP02765023A patent/EP1425277B8/fr not_active Expired - Lifetime
- 2002-09-13 AP APAP/P/2004/002982A patent/AP1818A/en active
- 2002-09-13 MX MXPA04002379A patent/MXPA04002379A/es active IP Right Grant
- 2002-09-13 ES ES02765023T patent/ES2316607T3/es not_active Expired - Lifetime
- 2002-09-13 IL IL16075502A patent/IL160755A0/xx unknown
- 2002-09-13 US US10/489,277 patent/US8063078B2/en not_active Expired - Fee Related
-
2004
- 2004-03-04 IL IL160755A patent/IL160755A/en not_active IP Right Cessation
- 2004-03-10 NO NO20041003A patent/NO327009B1/no not_active IP Right Cessation
- 2004-03-12 MA MA27573A patent/MA26216A1/fr unknown
- 2004-11-30 HK HK04109442.1A patent/HK1066534A1/xx unknown
-
2008
- 2008-12-04 NO NO20085077A patent/NO20085077L/no not_active Application Discontinuation
- 2008-12-04 NO NO20085078A patent/NO20085078L/no unknown
-
2009
- 2009-03-19 CY CY20091100306T patent/CY1109449T1/el unknown
- 2009-12-08 JP JP2009278584A patent/JP2010100632A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO327009B1 (no) | Nye forbindelser, fremgangsmate for fremstilling derav, anvendelse av forbindelsen samt farmasoytisk preparat omfattende denne | |
| US7531558B2 (en) | Carboxamide derivatives | |
| AU751139B2 (en) | Amide derivative | |
| DE60017115T2 (de) | Amid-derivate und deren medizinische verwendung | |
| NO322808B1 (no) | Pyrimidin derivater, samt anvendelse derav og farmasoytisk preparat. | |
| MX2008011016A (es) | Inhibidores de receptor sigma. | |
| RU2417987C2 (ru) | Ингибиторы сигма-рецептора | |
| UA71610C2 (uk) | Біциклічні гетероцикли та фармацевтична композиція на їх основі | |
| EP1147104A1 (fr) | Composes heterocycliques aromatiques utilises comme agents anti-inflammatoires | |
| WO2003005999A2 (fr) | Methodes permettant de traiter des maladies induites par les cytokines | |
| WO2001064676A2 (fr) | INHIBITEURS DE LA P38-α KINASE | |
| JP2010523692A (ja) | 新規合成物 | |
| EP1487821A1 (fr) | Piperidines substituees par benzodiazepine a utiliser dans le traitement de maladies cardiovasculaires | |
| EP0683166A1 (fr) | 3-Indolylpipéridines | |
| WO2001032648A1 (fr) | Nouveaux cyclopropanes utilises comme antagonistes de cgrp, medicaments contenant lesdits composes et procedes permettant de les preparer | |
| AU2019227770B2 (en) | Methyllactam ring compound and medicinal use thereof | |
| AU2012349290A1 (en) | Phenylpyrrole derivative | |
| KR101656906B1 (ko) | 피라졸 화합물 | |
| ES2330107T3 (es) | Derivados de urea heterociclicos para el tratamiento del dolor. | |
| US7514562B2 (en) | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | |
| US7528150B2 (en) | Urea derivatives having vanilloid receptor antagonist activity | |
| US20230339863A1 (en) | Indazole derivatives as cannabinoid receptor partial agonists | |
| KR20000029564A (ko) | 5ＨＴ2ｃ길항제및Ｄ2길항제를함유하는약제학적조성물 | |
| EP0684947A1 (fr) | Composes d'amide a activite pharmacologique | |
| CN108752360A (zh) | 一种治疗小儿腹泻的化合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |